Non-Cystic Fibrosis Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non-Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook
Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report
In May 2025, Jiangsu HengRui Medicine Co., Ltd. announced a study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis.
In May 2025, Genentech Inc. conducted a study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in patients with muco-obstructive disease.
DelveInsight's Non-Cystic Fibrosis Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non-Cystic Fibrosis Bronchiectasis treatment.
The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
Promising Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others.
Stay ahead with the most recent pipeline outlook for Non-Cystic Fibrosis Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Cystic Fibrosis Bronchiectasis Treatment Drugs
Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Profile
Brensocatib: Insmed Incorporated
Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation.
HSK31858: Haisco Pharmaceutical Group Co., Ltd.
HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.
CSL 787: CSL Behring
CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.
The Non-Cystic Fibrosis Bronchiectasis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
Non-Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market
Explore groundbreaking therapies and clinical trials in the Non-Cystic Fibrosis Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Non-Cystic Fibrosis Bronchiectasis Drugs
Non-Cystic Fibrosis Bronchiectasis Companies
Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Unveil the future of Non-Cystic Fibrosis Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report
Coverage- Global
Non-Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, Ciprofloxacin DPI (BAYQ3939) and others.
Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Non-Cystic Fibrosis Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Cystic Fibrosis Bronchiectasis Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Non‐cystic fibrosis bronchiectasis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non‐cystic fibrosis bronchiectasis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brensocatib: Insmed Incorporated
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
HSK31858: Haisco Pharmaceutical Group Co., Ltd.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CSL 787: CSL Behring
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Non‐cystic fibrosis bronchiectasis Key Companies
Non‐cystic fibrosis bronchiectasis Key Products
Non‐cystic fibrosis bronchiectasis- Unmet Needs
Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers
Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion
Non‐cystic fibrosis bronchiectasis Analyst Views
Non‐cystic fibrosis bronchiectasis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 hours ago
- Globe and Mail
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings
Globe and Mail
20 hours ago
- Globe and Mail
From Scrubs to Coats: Zenir Introduces New White Lab Coat Collection for Healthcare Professionals
Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Torrance, California--(Newsfile Corp. - June 14, 2025) - Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Known for combining functional innovation with elevated style, Zenir continues to raise the standard for medical workwear with this new release. To view an enhanced version of this graphic, please visit: The newly launched white lab coats faithfully embody Zenir's philosophy of comfort, practicality, and refined style. The short-length lab coat is engineered with a three-dimensional pattern that naturally facilitates shoulder and arm movement ideal for dynamic, active roles while the long lab coat features a subtly cinched waistline and matte hidden snap buttons to deliver a sleek, professional silhouette in clinical settings. Meticulously designed storage details, such as a dedicated pen holder in the chest pocket and an inner pocket for smartphones, balance functionality with clean design. Optimized for fast-paced healthcare environments, this collection not only meets workplace requirements but also offers a range of fits and style options to suit every body shape and individual preference. Already recognized for its high-performance scrubs, Zenir is a brand trusted by thousands in the healthcare industry and has sold more than 3 million units globally. The brand has earned its reputation for premium-quality scrubs that are breathable, durable, wrinkle-resistant, and moisture-wicking, now extended to its latest line of white lab coats. As Zenir continues to grow its presence beyond Korea, this expansion into white lab coats marks a milestone in Zenir's commitment to offering a complete spectrum of medical workwear solutions. With thoughtfully tailored cuts, sustainable production using GRS-certified recycled fibers, and a design-first approach, Zenir's new white lab coats are built for professionals who expect more from their daily uniform. For more details, visit
Globe and Mail
a day ago
- Globe and Mail
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. UnitedHealth Group Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. 2. Merck Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
